FOLFIRINOX后立体定向放疗治疗局部晚期胰腺癌的II期长期结果
LAPC-1多中心II期研究纳入50例组织学证实的不可手术局部晚期胰腺癌患者,诱导8周期FOLFIRINOX后无进展者接受40 Gy/5次SBRT。全组1年、3年OS分别为62%和10%;SBRT组中位OS 18个月 vs 非SBRT组5个月(p<0.001);7例术后根治性切除,切除组3年OS 43% vs 未切除组6.5%(p=0.03)。
要点
- FOLFIRINOX后SBRT在LAPC中显示长期生存,全组3年OS为10%。
- SBRT组中位OS 18个月,显著优于非SBRT组的5个月(p<0.001)。
- 7例实现根治性切除,切除组3年OS 43%显著优于未切除组6.5%。
核心结论
- LAPC患者接受FOLFIRINOX后SBRT可获得长期生存,并提高根治性手术概率,切除患者生存显著优于未切除者。
研究设计与样本
- 多中心II期研究(LAPC-1),纳入组织学证实的初诊不可手术LAPC患者。
- 诱导8周期FOLFIRINOX,无疾病进展者接受SBRT总剂量40 Gy分5次。
主要发现
- 共纳入50例,因化疗期间疾病进展11例,最终39例接受FOLFIRINOX后SBRT。
- 全组1年和3年OS分别为62%和10%,中位随访13个月。
- SBRT组中位OS 18个月(95%CI 13.2-21.5),非SBRT组5个月(95%CI 4.1-6.7),p<0.001。
- 放化疗后7例接受手术并实现根治性切除,切除组3年OS 43% vs 未切除组6.5%(p=0.03)。
- SBRT期间4例出现≥3级不良事件。
关键数值与推荐
- SBRT总剂量40 Gy分5次,用于FOLFIRINOX后无疾病进展的LAPC患者。
临床怎么用
- 对初诊不可手术LAPC,可考虑FOLFIRINOX诱导后无进展者行SBRT,并评估根治性手术可能性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the long-term outcome of a multicenter phase II study with FOLFIRINOX followed by stereotactic body radiotherapy (LAPC-1 trial) in patients with locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Patients with histological confirmation of LAPC inoperable at diagnosis were enrolled. Induction therapy with 8 cycles of FOLFIRINOX was administered. If no disease progression was found after chemotherapy, patients received stereotactic body radiotherapy (SBRT) at a total dose of 40 Gy in 5 fractions. RESULTS: In LAPC-1 trial, 50 patients were included, but due to disease progression in 11 patients under chemotherapy, 39 patients received stereotactic SBRT after FOLFIRINOX treatment. In whole population, the 1- and 3-year overall survival (OS) were 62% and 10%, respectively. Median follow-up was 13 months. The SBRT group had median OS of 18 months (95% CI 13.2-21.5) versus 5 months (95% CI 4.1-6.7) in non-SBRT group (p<0.001). After chemoradiotherapy, seven patients underwent surgery achieving a radical resection. Patients who underwent surgery had a 3-years OS of 43% compared to 6.5% in the unresected group (p=0.03). Four patients developed grade ≥ 3 adverse events during SBRT. CONCLUSIONS: Long-term survival has been found in patients with LAPC underwent FOLFIRINOX followed by SBRT. This approach increased the probability of a radical surgery. The resected patients achieved a significant better survival compared to unresected group.
引用
- Teriaca MA, Loi M, Suker M, et al. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother Oncol. 2020. PMID: 33217500. doi:10.1016/j.radonc.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。